#ES­MO17 ROUNDUP: Mer­ck’s da­ta on Keytru­da/chemo com­bo for lung can­cer takes ear­ly spot­light at ES­MO

MADRID — Mer­ck’s ab­stract $MRK on its big study of Keytru­da (pem­brolizum­ab) com­bined with chemo hit ear­ly at ES­MO, at­tract­ing con­sid­er­able at­ten­tion for the im­pres­sive …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER